Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity

Human Gene Therapy

Volumn 20, Issue 12, 2009, Pages 1652-1664

  Hu, Biliang ^a   Yang, Haiguang ^a   Dai, Bingbing ^a   Tai, April ^a   Wang, Pin ^a  

^a University of Southern California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; LENTIVIRUS VECTOR; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS; CANCER VACCINES; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HIV INTEGRASE; HIV-1; IMMUNOTHERAPY, ACTIVE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS; OVALBUMIN; TRANSDUCTION, GENETIC; TRANSGENES; VIRAL ENVELOPE PROTEINS; VIRUS INTEGRATION;

MUS;

EID: 74549131608     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.012     Document Type: Article

References (49)

1. Apolonia, L., Waddington, S.N., Fernandes, C., Ward, N.J., Bouma, G., Blundell, M.P., Thrasher, A.J., Collins, M.K., and Philpott, N.J. (2007). Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol. Ther. 15, 1947-1954.
2. Banchereau, J., and Palucka, A.K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306. (Pubitemid 40516155)
3. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
4. Barnden, M.J., Allison, J., Heath, W.R., and Carbone, F.R. (1998). Defective TCR expression in transgenic mice constructed using cDNA-based a-and b-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34-40.
5. Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., and Kafri, T. (2008). A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol. Ther. 16, 1968-1976.
6. Bohne, J., and Cathomen, T. (2008). Genotoxicity in gene therapy: An account of vector integration and designer nucleases. Curr. Opin. Mol. Ther. 10, 214-223.
7. Bokhoven, M., Stephen, S.L., Knight, S., Gevers, E.F., Robinson, I.C., Takeuchi, Y., and Collins, M.K. (2009). Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83, 283-294.
8. Breckpot, K., Aerts, J.L., and Thielemans, K. (2007). Lentiviral vectors for cancer immunotherapy: Transforming infectious particles into therapeutics. Gene Ther. 14, 847-862.
9. Butler, S.L., Hansen, M.S., and Bushman, F.D. (2001). A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7, 631-634.
10. Coutant, F., Frenkiel, M.P., Despres, P., and Charneau, P. (2008). Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE 3, e3973.
11. Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., and Naldini, L. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471.
12. Dullaers, M., and Thielemans, K. (2006). From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J. Gene Med. 8, 3-17.
13. Dullaers, M., Van Meirvenne, S., Heirman, C., Straetman, L., Bonehill, A., Aerts, J.L., Thielemans, K., and Breckpot, K. (2006). Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13, 630-640.
14. + T cell responses. J. Clin. Invest. 111, 1673-1681.
15. Cavazzana-Calvo, M. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
16. + T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24, 643-656.
17. He, Y., Munn, D., and Falo, L.D., Jr. (2007). Recombinant lenti-vector as a genetic immunization vehicle for antitumor immunity. Expert Rev. Vaccines 6, 913-924.
18. Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bev-an, M.J., and Carbone, F.R. (1994). T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27.
19. Iglesias, M.C., Mollier, K., Beignon, A.S., Souque, P., Adotevi, O., Lemonnier, F., and Charneau, P. (2007). Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol. Ther. 15, 1203-1210.
20. Karwacz, K., Mukherjee, S., Apolonia, L., Blundell, M.P., Bouma, G., Escors, D., Collins, M.K., and Thrasher, A.J. (2009). Non-integrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J. Virol. 83, 3094-3103.
21. Kim, J.H., Majumder, N., Lin, H., Watkins, S., Falo, L.D., Jr., and You, Z. (2005). Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther. 16, 1255-1266.
22. Kimura, T., Koya, R.C., Anselmi, L., Sternini, C., Wang, H.J., Comin-Anduix, B., Prins, R.M., Faure-Kumar, E., Rozengurt, N., Cui, Y., Kasahara, N., and Stripecke, R. (2007). Lentiviral vectors with CMV or MHCII promoters administered in vivo: Immune reactivity versus persistence of expression. Mol. Ther. 15, 1390-1399.
23. Kohn, D.B. (2007). Lentiviral vectors ready for prime-time. Nat. Biotechnol. 25, 65-66.
24. Leavitt, A.D., Robles, G., Alesandro, N., and Varmus, H.E. (1996). Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J. Virol. 70, 721-728.
25. Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., Von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B., and Baum, C. (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497.
26. Lois, C., Hong, E.J., Pease, S., Brown, E.J., and Baltimore, D. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872.
27. + T-cell responses. J. Virol. 82, 86-95.
28. Melief, C.J. (2008). Cancer immunotherapy by dendritic cells. Immunity 29, 372-383.
29. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., Shinn, P., Chen, H., Berry, C.C., Ecker, J.R., and Bushman, F.D. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234.
30. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, L., Benedicenti, F., Ambrosi, A., Di Serio, C., Doglioni, C., Von Kalle, C., and Naldini, L. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696.
31. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
32. Negri, D.R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M.E., and Cara, A. (2007). Successful immunization with a single injection of non-integrating lentiviral vector. Mol. Ther. 15, 1716-1723.
33. Nienhuis, A.W., Dunbar, C.E., and Sorrentino, B.P. (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031-1049.
34. Nightingale, S.J., Hollis, R.P., Pepper, K.A., Petersen, D., Yu, X.J., Yang, C., Bahner, I., and Kohn, D.B. (2006). Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 13, 1121-1132.
35. Palmowski, M.J., Lopes, L., Ikeda, Y., Salio, M., Cerundolo, V., and Collins, M.K. (2004). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 172, 1582-1587.
36. Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., and Serguera, C. (2006). Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 17684-17689.
37. Philpott, N.J., and Thrasher, A.J. (2007). Use of nonintegrating lentiviral vectors for gene therapy. Hum. Gene Ther. 18, 483-489.
38. Rowe, H.M., Lopes, L., Ikeda, Y., Bailey, R., Barde, I., Zenke, M., Chain, B.M., and Collins, M.K. (2006). Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 13, 310-319.
39. Saenz, D.T., Loewen, N., Peretz, M., Whitwam, T., Barraza, R., Howell, K.G., Holmes, J.M., Good, M., and Poeschla, E.M. (2004). Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: Analysis with class I integrase mutants. J. Virol. 78, 2906-2920.
40. Schroder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., and Bushman, F. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529.
41. Seggewiss, R., Pittaluga, S., Adler, R.L., Guenaga, F.J., Ferguson, C., Pilz, I.H., Ryu, B., Sorrentino, B.P., Young, W.S., III, Donahue, R.E., Von Kalle, C., Nienhuis, A.W., and Dunbar, C.E. (2006). Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107, 3865-3867.
42. Steinman, R.M., and Banchereau, J. (2007). Taking dendritic cells into medicine. Nature 449, 419-426.
43. Vandendriessche, T., Thorrez, L., Naldini, L., Follenzi, A., Moons, L., Berneman, Z., Collen, D., and Chuah, M.K. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100, 813-822.
44. Vargas, J., Jr., Gusella, G.L., Najfeld, V., Klotman, M.E., and Cara, A. (2004). Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum. Gene Ther. 15, 361-372.
45. Verma, I.M., and Weitzman, M.D. (2005). Gene therapy: Twenty-first century medicine. Annu. Rev. Biochem. 74, 711-738.
46. Vigna, E., and Naldini, L. (2000). Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2, 308-316.
47. Yanez-Munoz, R.J., Balaggan, K.S., Macneil, A., Howe, S.J., Schmidt, M., Smith, A.J., Buch, P., Maclaren, R.E., Anderson, P.N., Barker, S.E., Duran, Y., Bartholomae, C., Von Kalle, C., Heckenlively, J.R., Kinnon, C., Ali, R.R., and Thrasher, A.J. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348-353.
48. Yang, L., and Baltimore, D. (2005). Long-term in vivo provision of antigen-specific T cell immunity by programming hema-topoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 102, 4518-4523.
49. Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K.I., Ziegler, L., Elliot, A., Walls, A., Yu, D., Baltimore, D., and Wang, P. (2008). Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26, 326-334.